Both doses of pozdeutinurad met the primary efficacy endpoint, defined as the proportion of patients achieving a serum uric acid (sUA) level <6 mg/dL at month 6 (75 mg: 69.2% vs 8.1%; p<0.0001; 50 mg: 56.6% vs 8.1%; p<0.0001). The safety profile was consistent with previous studies.

“We are very encouraged by these results and their implications for patients whose gout remains inadequately controlled,” says Lydia Abad-Franch, MD, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi. “These findings, including sustained urate lowering and a favourable efficacy and tolerability profile, support the potential of pozdeutinurad to address a significant unmet need and provide a strong foundation for regulatory submissions.”

Added to Sobi’s global development portfolio in February 2026

Pozdeutinurad was added to Sobi’s global development portfolio in February 2026 following its acquisition of Arthrosi, a biotechnology company focused on developing treatments for gout, and further enhances Sobi’s presence in this area. 

Pozdeutinurad is being investigated in two global Phase 3 studies, REDUCE 1 and REDUCE 2 which are 12-month, randomised, double-blind, placebo-controlled trials designed to evaluate pozdeutinurad in patients with gout, including those with tophaceous gout. REDUCE 1 and REDUCE 2 enrolled more than 800 patients each. REDUCE 1 is fully enrolled, and data are expected in the second half of 2026.